Calcium channels and their involvement in cardiovascular disease.
The widespread distribution of L-type Ca2+ channels in the cardiovascular system makes that system a natural 'target' for drugs which inhibit L-type Ca2+ channel activity. Now that tissue-dependent differences in the chemical composition of the calcium antagonist binding sites have been recognized it may be possible to develop drugs with enhanced tissue selectivity. The search for new compounds should not be restricted to improvements in tissue selectivity, however. Some of the ancillary properties of the L-type Ca2+ channel inhibitors--including their ability to protect against lipid peroxidation--should not be lost because these ancillary properties may contribute significantly to their usefulness as therapeutic agents.
Nayler
W G
WG
Department of Medicine, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia.
D001665:Binding Sites; D002545:Brain Ischemia / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000378:metabolism*; D015220:Calcium Channels / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000378:metabolism*; D015195:Drug Design; D006801:Humans
D002121:Calcium Channel Blockers; D015220:Calcium Channels